| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/10/2003 | US20030068792 Therapeutic agent for use in the treatment of infections and cancer disorders |
| 04/10/2003 | US20030068641 Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| 04/10/2003 | US20030068407 A particulate formulation containing an oil of a vitamin, an oil containing one or more vitamin or a derivative, a gelling agent of vegetable origin having a glass transition point greater than 20 degree C. and a protein except gelatin |
| 04/10/2003 | US20030068384 Polymeric drug formulations |
| 04/10/2003 | US20030068381 Induced phase transition method for the production of microparticles containing hydrophilic active agents |
| 04/10/2003 | US20030068379 A molecular carrier containing a central multivalent core and multiple adduct molecules bonded with core, wherein adduct represents adduct moieties which can be the same of different from one another and are residues of amino acids |
| 04/10/2003 | US20030068378 Mucosal surface-coat-forming film dosage units containing a water-soluble hydrocolloid, an effective dose of a sexual dysfunction active agent and a mucosal adhesion enhancer, wherein mucosal adhesion enhancer is a starch graft copolymer |
| 04/10/2003 | US20030068377 PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water |
| 04/10/2003 | US20030068369 Comprising plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising solid matrix of polymer which contains drug, sub-units being connected together in assembled dosage form by a weld |
| 04/10/2003 | US20030068367 Systems, methods and apparatuses for manufacturing dosage forms |
| 04/10/2003 | US20030068364 Pro-liposomal encapsulated preparations (iv) |
| 04/10/2003 | US20030068363 Complexes consisting of an isolated major histocompatibility complex component and an autoantigenic peptide associated with the antigen binding site of the component; useful in treating autoimmune disease |
| 04/10/2003 | US20030068362 Methods and formulations for the delivery of pharmacologically active agents |
| 04/10/2003 | US20030068361 For treating hyperglycemia and related disorders |
| 04/10/2003 | US20030068360 DNA vaccines for farm animals, in particular bovines and porcines |
| 04/10/2003 | US20030068356 Sequential drug delivery systems |
| 04/10/2003 | US20030068350 .1-6% of a hydrophobically modified, alkali-soluble copolymer thickener, .05-2% of a polysaccharide hydrocolloid or polyalkylene glycol, a neutralizing amount of alkali and the balance water |
| 04/10/2003 | US20030068341 Oil in water emulsion cream that has maxacalcitol present in both oil and water phases |
| 04/10/2003 | US20030068340 Pharmaceutically non-toxic amount of an oligosaccharide capable of forming an association or complex with aqueous 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-(4-(2-morpholin -4-yl- ethoxy)-naphthalen-1-yl)-urea; antiinflammatories |
| 04/10/2003 | US20030068339 Veterinary florfenicol formulation that is syringeable under cold weather conditions |
| 04/10/2003 | US20030068336 Purified capsular polysaccharides from Neisseria meningitidis serogroups are activated and attached to a carriers protein |
| 04/10/2003 | US20030068331 Dressing for treatment of a dermatological disease comprised of a gum resin, a topically acceptable volatile solvent, and a pharmacologically active agent |
| 04/10/2003 | US20030068324 Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid |
| 04/10/2003 | US20030068323 Hybrid compositions for intracellular targeting |
| 04/10/2003 | US20030068322 Methods of antibody-directed enzyme-prodrug therapy |
| 04/10/2003 | US20030068315 The polysaccharides in the complexes form an envelope which protects and carries immunoglobulins allowing their systemic absorption through gastric and mucosal membrane; polysacchride and immunoglobulins are bonded by ionic bonds |
| 04/10/2003 | US20030068280 Treatment of respiratory diseases |
| 04/10/2003 | US20030068277 Particles for inhalation having sustained release properties |
| 04/10/2003 | US20030068276 Dosage forms |
| 04/10/2003 | US20030068250 For contact lenses |
| 04/10/2003 | US20030066800 Enteric coatings for drugs; sustained rlease |
| 04/10/2003 | US20030066753 Stable taurolidine electrolyte solutions |
| 04/10/2003 | US20030066525 Pressurised metered dose inhalers (MDI) |
| 04/10/2003 | US20030066524 Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage |
| 04/10/2003 | DE19929511C2 Hochkonzentriert fließfähige Aniontensidmischungen Highly concentrated flowable anionic surfactant mixtures |
| 04/10/2003 | CA2722319A1 Water-in-oil emulsions with ethylene oxide groups, compostions, and methods |
| 04/10/2003 | CA2462661A1 A method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same |
| 04/10/2003 | CA2462602A1 Double stranded rna as an adjuvant in vaccine compositions |
| 04/10/2003 | CA2462599A1 Storage-stable fibrinogen solutions |
| 04/10/2003 | CA2462596A1 Storage-stable human fibrinogen solutions |
| 04/10/2003 | CA2462425A1 Therapeutically useful triethyleneglycol cholesteryl oligonucleotides |
| 04/10/2003 | CA2462072A1 Flavor-active peptides |
| 04/10/2003 | CA2462004A1 Systems, methods and apparatuses for manufacturing dosage forms |
| 04/10/2003 | CA2461971A1 Encapsulated materials |
| 04/10/2003 | CA2461877A1 Method of treatment using ligand-immunogen conjugates |
| 04/10/2003 | CA2461715A1 Proliferation and differentiation of stem cells using extracellular matrix and other molecules |
| 04/10/2003 | CA2461618A1 Ibuprofen salt emulsifiers and cream formulations containing same |
| 04/10/2003 | CA2461553A1 Water-in-oil emulsions comprising vinyl polymers carrying acidic groups in side chains, compositions, and methods |
| 04/10/2003 | CA2461099A1 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| 04/10/2003 | CA2460916A1 Methods and compositions for modulating interleukin-21 receptor activity |
| 04/10/2003 | CA2460486A1 Pseudopolymorphic forms of carvedilol |
| 04/10/2003 | CA2460167A1 Aqueous ecabet sodium solution preparation |
| 04/09/2003 | EP1300424A1 Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use |
| 04/09/2003 | EP1300394A1 Method for the production of a water-dispersible formulation containing carotenoids |
| 04/09/2003 | EP1300160A1 Method of stabilizing preparation |
| 04/09/2003 | EP1300152A1 Percutaneous absorption type steroid preparation for external use |
| 04/09/2003 | EP1300143A1 Patch containing 4-biphenylacetic acid |
| 04/09/2003 | EP1300139A2 Medicament excipient particles for tissue-specific application of a medicament |
| 04/09/2003 | EP1299541A2 Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses |
| 04/09/2003 | EP1299522A2 Alteration of cell membrane |
| 04/09/2003 | EP1299494A2 Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
| 04/09/2003 | EP1299415A1 Chemokine receptor modulators, production and use |
| 04/09/2003 | EP1299352A2 Compounds to treat alzheimer's disease |
| 04/09/2003 | EP1299349A2 Compounds to treat alzheimer's disease |
| 04/09/2003 | EP1299348A1 Compounds and compositions for delivering active agents |
| 04/09/2003 | EP1299287A1 Methods of producing a terminally sterilized topical patch preparation |
| 04/09/2003 | EP1299157A1 Composition and applicator for topical substance delivery |
| 04/09/2003 | EP1299134A1 The use of honey in wound dressings |
| 04/09/2003 | EP1299132A2 Limiting the presence of microorganisms using polymer-bound metal-containing compositions |
| 04/09/2003 | EP1299125A1 Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| 04/09/2003 | EP1299124A2 Composition for aqueous stabilization of fat-soluble vitamins |
| 04/09/2003 | EP1299114A1 Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase |
| 04/09/2003 | EP1299108A1 A parasiticidal formulation and a method of making this formulation |
| 04/09/2003 | EP1299107A2 Highly concentrated stable meloxicam solutions |
| 04/09/2003 | EP1299104A1 Tamper-resistant oral opioid agonist formulations |
| 04/09/2003 | EP1299096A1 Prostaglandin compounds for treating congestive heart failure |
| 04/09/2003 | EP1299095A1 Clear aqueous anaesthetic composition |
| 04/09/2003 | EP1299090A1 Oral pharmaceutical composition with controlled release and prolonged absorption |
| 04/09/2003 | EP1299089A2 Drug delivery system for poorly water soluble drugs |
| 04/09/2003 | EP1299087A1 Microspheres and adjuvants for dna vaccine delivery |
| 04/09/2003 | EP1299086A1 Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives |
| 04/09/2003 | EP1299085A2 Improved liposomal camptothecins and uses thereof |
| 04/09/2003 | EP1299084A2 Liposomal antineoplastic drugs and uses thereof |
| 04/09/2003 | EP1299083A1 Low molecular weight polymeric compositions |
| 04/09/2003 | EP1299081A1 Use of oligosaccharides to stimulate beta-endorphin production |
| 04/09/2003 | EP1299068A1 Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions |
| 04/09/2003 | EP1299048A1 Biodegradable vehicles and delivery systems of biologically active substances |
| 04/09/2003 | EP1298994A2 Method for opening the blood-brain barrier |
| 04/09/2003 | EP1140117B1 Aciclovir compositions containing dimethicone |
| 04/09/2003 | EP1037587B1 Site-specific preparation of polyethylene glycol-grf conjugates |
| 04/09/2003 | EP1035837B1 Lipid compositions and their use |
| 04/09/2003 | EP1003568B1 Hemostatic tissue sealants |
| 04/09/2003 | EP1003477B1 Therapeutical system for transdermal delivery of levonorgestrel |
| 04/09/2003 | EP0994701B1 Block copolymer |
| 04/09/2003 | EP0948320B1 PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF THE HMG-CoA REDUCTASE INHIBITOR FLUVASTATIN |
| 04/09/2003 | EP0938302B1 Pleasant-tasting aqueous liquid composition of a bitter-tasting drug |
| 04/09/2003 | EP0859597B1 Sustained release delivery system and long acting narcotic analgesics and antagonists |
| 04/09/2003 | EP0827396B1 Production scale method of forming microparticles |
| 04/09/2003 | EP0806940B1 Aerosol drug formulations |
| 04/09/2003 | EP0804552B1 Redirection of cellular immunity by receptor chimeras |